Chimerix

Novel therapeutics to prevent and treat life-threatening viral infections

Chimerix (NASDAQ: CMRX) is an anti-viral drug discovery and development company leveraging a proprietary lipid-conjugate technology to enhance oral absorption and improve antiviral potency. The company's lead product is brincidofovir, an oral broad-spectrum antiviral with potent activity against DNA viruses. Brincidofovir is being developed to prevent and treat infections in a number of patient populations, including prevention of cytomegalovirus in transplant settings and treatment of adenovirus. Chimerix completed its IPO on NASDAQ in 2013.

Status

IPO in 2013 (NASDAQ: CMRX)

Year of Investment

2004

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Durham, North Carolina

Frazier Team

Website

Social Media